Navigation Links
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Date:12/1/2008

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need. A Prescription Drug User Fee Act (PDUFA) target date of April 2, 2009 has been established by the FDA for a decision regarding the approval of the Zevalin sBLA. If approved, Zevalin would be the first radioimmunotherapy available to patients as first-line consolidation therapy. It is estimated that there would be approximately 18,000 additional patients that currently receive first-line treatment which would potentially be eligible to use Zevalin under the proposed expanded label.

CTI and Spectrum Pharmaceuticals, Inc. entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, on November 26, 2008 to commercialize and develop ZEVALIN in the United States and expects the transaction will close in early December, 2008. CTI initially acquired the US rights to Zevalin from Biogen Idec in December 2007. CTI gained access to the First-line Indolent Trial (FIT) data through an agreement with Bayer Schering Pharma AG, Germany who used the data to obtain approval for Zevalin as first-line consolidation treatment in Europe.

"We are pleased that the FDA, by granting the application priority review status, acknowledges that the use of Zevalin in the first-line consolidation setting could represent an important treatment option for follicular B-cell non-Hodgkin's lymphoma patients," said James A. Bianco, M.D., CEO of Cell Therapeutic
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
2. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
3. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
4. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
5. FDA Accepts Immucors Response to Warning Letter
6. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
7. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
8. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
9. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
10. FDA Accepts Ranexa(R) sNDA and NDA for Filing
11. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Bill Jacobs Automotive, a group of car dealerships ... with the Heartland Blood Center and offering free oil change ... takes place Saturday, Jan. 18 at the Bill Jacobs Cadillac ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Corporation, an,orthopedic implants company focused on silicon nitride ... Drug Administration,has granted 510(k) marketing clearance to Amedica,s ... system is a low profile and modular pedicle,screw ... surgeons,greater flexibility in the positioning of these spinal ...
... Daval International Limited, a UK,private company, ... of a,London based Phase IIB trial of ... double-blind placebo-controlled cross-over study will seek to,detect ... patients with Secondary,Progressive Multiple Sclerosis, following open-label ...
... 26 H2Diesel Holdings, Inc. (OTC,Bulletin Board: HTWO) today ... Officer, effective December 1, 2007., Since 2004, Mr. ... Inc. where he led the Company,s finance and,information technology ... Chairman of the Board and CEO. From 2001 to ...
Cached Biology Technology:Amedica Receives FDA 510(k) Clearance for Valeo(TM) Pedicle Screw System 2H2Diesel Announces Appointment of Cary J. Claiborne as Chief Financial Officer 2H2Diesel Announces Appointment of Cary J. Claiborne as Chief Financial Officer 3
(Date:7/9/2014)... pain and fever but often can be defeated with antibiotics ... hard to beat. Now, scientists have built a new weapon ... Published in the journal ACS Applied Materials & Interfaces ... kill more of them than medicine alone. , David Leong, ... lie in wait, undetectable in the human body or in ...
(Date:7/9/2014)... U.S. may be on the verge of an economy driven ... cleaner than coal and is undergoing a production boom. It ... but recent research is casting serious doubts over just how ... & Engineering News (C&EN), the weekly news magazine of ... a senior correspondent at C&EN, explains that when burned as ...
(Date:7/9/2014)... results accrue. To completely and systematically archive this ... fact, researchers in the life sciences spend a ... an online survey of 70 people working in ... Applied Information Technology FIT in Sankt Augustin. Many ... centralized or structured approach to data collection in ...
Breaking Biology News(10 mins):Managing the data jungle 2Managing the data jungle 3
... delivers new insight about rapid toxin evolution in venomous snakes: ... race with opossums, a group of snake-eating American marsupials. Although ... this fact has not been factored into previous explanations for ... usually seen as a feeding, or trophic, adaptation. But new ...
... contrast agents that sneak into bacteria disguised as glucose ... sensitivity and specificity. These agents -- called maltodextrin-based imaging ... other inflammatory conditions. "These contrast agents fill the ... of bacteria in vivo and distinguish infections from other ...
... 18, 2011) Researchers from the John Theurer Cancer ... 14 cancer-related studies during the recently concluded American Society ... June 3 7, 2011 in Chicago. The studies ... treatment outcomes, and patient quality of life issues. ...
Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3New contrast agents detect bacterial infections with high sensitivity and specificity 2New contrast agents detect bacterial infections with high sensitivity and specificity 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6
... Escherichia coli RY 13 5'G AATTC3' 3'CTTAA G5' ... min or ethanol precipitation. Storage Conditions: 10mM Tris-HCl ... 0.15% Triton X-100, 0.01% BSA, 50% glycerol. Shipping ... -20C. Unit Definition: One unit is defined as ...
... LabWorks Software provides a comprehensive experiment based ... drop down menus yet sophisticated and powerful ... dozens of CCD cameras for easy image ... , Automated Digital Video Playback ...
... Heavy duty stainless-steel shaker flask clips, purpose-designed ... speeds. All clips are equipped with ... 1L.) also include a bottom retainer spring, ... scratching of expensive glassware. Clips include ...
... mix (Thermoprime Plus DNA Polymerase with a ... times higher fidelity than standard Taq DNA ... DNA polymerase, Amplifies DNA templates >20kb, Concentration: ... PCR for cloning and mutagenesis We are ...
Biology Products: